Why the study?
Does intravenous acetylsalicylic acid (250 mg or 500 mg) improve platelet inhibition at 5 minutes compared to oral 300 mg acetylsalicylic acid in ASA-naïve patients with acute coronary syndromes?
Population
270 ASA naïve patients with acute coronary syndromes (ACS) < 24 hours
Comparison
Single dose of intravenous acetylsalicylic acid… vs Single dose of oral acetylsalicylic acid (300 mg)
Design
RCT, randomised into one of three treatment arms
Follow-up
5 minutes
Authors
Loading...
Supports IV ASA for rapid platelet inhibition in ACS; confirms faster TXB2 suppression versus oral loading.
Does intravenous acetylsalicylic acid (250 mg or 500 mg) improve platelet inhibition at 5 minutes compared to oral 300 mg acetylsalicylic acid in ASA-naïve patients with acute coronary syndromes?
Intravenous administration of 250 mg or 500 mg acetylsalicylic acid provides faster and more complete inhibition of thromboxane generation and platelet aggregation at 5 minutes compared to 300 mg oral administration in ASA-naïve ACS patients.
Hohlfeld et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: